271 related articles for article (PubMed ID: 36275711)
1. Lipids for CD8
Wu D; Chen Y
Front Immunol; 2022; 13():1020422. PubMed ID: 36275711
[TBL] [Abstract][Full Text] [Related]
2. Enhancing CD8
Zhang Y; Kurupati R; Liu L; Zhou XY; Zhang G; Hudaihed A; Filisio F; Giles-Davis W; Xu X; Karakousis GC; Schuchter LM; Xu W; Amaravadi R; Xiao M; Sadek N; Krepler C; Herlyn M; Freeman GJ; Rabinowitz JD; Ertl HCJ
Cancer Cell; 2017 Sep; 32(3):377-391.e9. PubMed ID: 28898698
[TBL] [Abstract][Full Text] [Related]
3. Uptake of oxidized lipids by the scavenger receptor CD36 promotes lipid peroxidation and dysfunction in CD8
Xu S; Chaudhary O; Rodríguez-Morales P; Sun X; Chen D; Zappasodi R; Xu Z; Pinto AFM; Williams A; Schulze I; Farsakoglu Y; Varanasi SK; Low JS; Tang W; Wang H; McDonald B; Tripple V; Downes M; Evans RM; Abumrad NA; Merghoub T; Wolchok JD; Shokhirev MN; Ho PC; Witztum JL; Emu B; Cui G; Kaech SM
Immunity; 2021 Jul; 54(7):1561-1577.e7. PubMed ID: 34102100
[TBL] [Abstract][Full Text] [Related]
4. Acetyl-CoA carboxylase obstructs CD8
Hunt EG; Hurst KE; Riesenberg BP; Kennedy AS; Gandy EJ; Andrews AM; Del Mar Alicea Pauneto C; Ball LE; Wallace ED; Gao P; Meier J; Serody JJ; Coleman MF; Thaxton JE
Cell Metab; 2024 May; 36(5):969-983.e10. PubMed ID: 38490211
[TBL] [Abstract][Full Text] [Related]
5. CD226 identifies functional CD8
Huang H; Huang Z; Ge J; Yang J; Chen J; Xu B; Wu S; Zheng X; Chen L; Zhang X; Jiang J
Front Immunol; 2023; 14():1150803. PubMed ID: 37056782
[TBL] [Abstract][Full Text] [Related]
6. Functional Heterogeneity of CD4
Oja AE; Piet B; van der Zwan D; Blaauwgeers H; Mensink M; de Kivit S; Borst J; Nolte MA; van Lier RAW; Stark R; Hombrink P
Front Immunol; 2018; 9():2654. PubMed ID: 30505306
[TBL] [Abstract][Full Text] [Related]
7. TOX-expressing terminally exhausted tumor-infiltrating CD8
Han HS; Jeong S; Kim H; Kim HD; Kim AR; Kwon M; Park SH; Woo CG; Kim HK; Lee KH; Seo SP; Kang HW; Kim WT; Kim WJ; Yun SJ; Shin EC
Cancer Lett; 2021 Feb; 499():137-147. PubMed ID: 33249194
[TBL] [Abstract][Full Text] [Related]
8. CD147 regulates antitumor CD8
Chen Y; Xu J; Wu X; Yao H; Yan Z; Guo T; Wang W; Wang P; Li Y; Yang X; Li H; Bian H; Chen ZN
Cell Mol Immunol; 2021 Aug; 18(8):1995-2009. PubMed ID: 33177695
[TBL] [Abstract][Full Text] [Related]
9. Distinct exhaustion features of T lymphocytes shape the tumor-immune microenvironment with therapeutic implication in patients with non-small-cell lung cancer.
Kim CG; Kim G; Kim KH; Park S; Shin S; Yeo D; Shim HS; Yoon HI; Park SY; Ha SJ; Kim HR
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34907028
[TBL] [Abstract][Full Text] [Related]
10. 4-1BB Delineates Distinct Activation Status of Exhausted Tumor-Infiltrating CD8
Kim HD; Park S; Jeong S; Lee YJ; Lee H; Kim CG; Kim KH; Hong SM; Lee JY; Kim S; Kim HK; Min BS; Chang JH; Ju YS; Shin EC; Song GW; Hwang S; Park SH
Hepatology; 2020 Mar; 71(3):955-971. PubMed ID: 31353502
[TBL] [Abstract][Full Text] [Related]
11. The role of tumor-infiltrating lymphocytes in cholangiocarcinoma.
Liu D; Heij LR; Czigany Z; Dahl E; Lang SA; Ulmer TF; Luedde T; Neumann UP; Bednarsch J
J Exp Clin Cancer Res; 2022 Apr; 41(1):127. PubMed ID: 35392957
[TBL] [Abstract][Full Text] [Related]
12. Adenosine mediates functional and metabolic suppression of peripheral and tumor-infiltrating CD8
Mastelic-Gavillet B; Navarro Rodrigo B; Décombaz L; Wang H; Ercolano G; Ahmed R; Lozano LE; Ianaro A; Derré L; Valerio M; Tawadros T; Jichlinski P; Nguyen-Ngoc T; Speiser DE; Verdeil G; Gestermann N; Dormond O; Kandalaft L; Coukos G; Jandus C; Ménétrier-Caux C; Caux C; Ho PC; Romero P; Harari A; Vigano S
J Immunother Cancer; 2019 Oct; 7(1):257. PubMed ID: 31601268
[TBL] [Abstract][Full Text] [Related]
13. Accumulation of long-chain fatty acids in the tumor microenvironment drives dysfunction in intrapancreatic CD8+ T cells.
Manzo T; Prentice BM; Anderson KG; Raman A; Schalck A; Codreanu GS; Nava Lauson CB; Tiberti S; Raimondi A; Jones MA; Reyzer M; Bates BM; Spraggins JM; Patterson NH; McLean JA; Rai K; Tacchetti C; Tucci S; Wargo JA; Rodighiero S; Clise-Dwyer K; Sherrod SD; Kim M; Navin NE; Caprioli RM; Greenberg PD; Draetta G; Nezi L
J Exp Med; 2020 Aug; 217(8):. PubMed ID: 32491160
[TBL] [Abstract][Full Text] [Related]
14. Fatty Acid Oxidation Controls CD8
Lin R; Zhang H; Yuan Y; He Q; Zhou J; Li S; Sun Y; Li DY; Qiu HB; Wang W; Zhuang Z; Chen B; Huang Y; Liu C; Wang Y; Cai S; Ke Z; He W
Cancer Immunol Res; 2020 Apr; 8(4):479-492. PubMed ID: 32075801
[TBL] [Abstract][Full Text] [Related]
15. Deletion of Cbl-b inhibits CD8
Kumar J; Kumar R; Kumar Singh A; Tsakem EL; Kathania M; Riese MJ; Theiss AL; Davila ML; Venuprasad K
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33462140
[TBL] [Abstract][Full Text] [Related]
16. Tumor microenvironment in triple-negative breast cancer: the correlation of tumor-associated macrophages and tumor-infiltrating lymphocytes.
Kuroda H; Jamiyan T; Yamaguchi R; Kakumoto A; Abe A; Harada O; Masunaga A
Clin Transl Oncol; 2021 Dec; 23(12):2513-2525. PubMed ID: 34089486
[TBL] [Abstract][Full Text] [Related]
17. PD-1+ Tim3+ tumor-infiltrating CD8 T cells sustain the potential for IFN-γ production, but lose cytotoxic activity in ovarian cancer.
Sawada M; Goto K; Morimoto-Okazawa A; Haruna M; Yamamoto K; Yamamoto Y; Nakagawa S; Hiramatsu K; Matsuzaki S; Kobayashi E; Kawashima A; Hirata M; Iwahori K; Kimura T; Ueda Y; Kimura T; Wada H
Int Immunol; 2020 May; 32(6):397-405. PubMed ID: 32009163
[TBL] [Abstract][Full Text] [Related]
18. Effector, Memory, and Dysfunctional CD8(+) T Cell Fates in the Antitumor Immune Response.
Reiser J; Banerjee A
J Immunol Res; 2016; 2016():8941260. PubMed ID: 27314056
[TBL] [Abstract][Full Text] [Related]
19. CD28 costimulation drives tumor-infiltrating T cell glycolysis to promote inflammation.
Beckermann KE; Hongo R; Ye X; Young K; Carbonell K; Healey DCC; Siska PJ; Barone S; Roe CE; Smith CC; Vincent BG; Mason FM; Irish JM; Rathmell WK; Rathmell JC
JCI Insight; 2020 Aug; 5(16):. PubMed ID: 32814710
[TBL] [Abstract][Full Text] [Related]
20. Tumor-infiltrating lymphocytes are functionally inactivated by CD90+ stromal cells and reactivated by combined Ibrutinib and Rapamycin in human pleural mesothelioma.
Yang H; Berezowska S; Dorn P; Zens P; Chen P; Peng RW; Marti TM; Kocher GJ; Schmid RA; Hall SRR
Theranostics; 2022; 12(1):167-185. PubMed ID: 34987640
[No Abstract] [Full Text] [Related]
[Next] [New Search]
